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presumed to be related to his chemotherapy; and died of 
neutropaenic sepsis. 
 
Conclusion: Our study shows VMAT chemoradiotherapy 
delivers excellent local control in the treatment of advanced 
anal cancers. Treatment was well tolerated and all patients 
completed the prescribed course of radiotherapy. More data 
is needed and longer term follow-up to confirm clinical 
outcomes.  
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Purpose or Objective: Neoadjuvant chemoradiation followed 
by surgery is the standard of care for locally advanced rectal 
cancer (LARC).  
The aim of this study was to identify predictive factors of 
tumor responsiveness. 
 
Material and Methods: A retrospective study was carried out 
on a series of 243 patients with histologically proven LARC 
treated between 2000 and 2014 by preoperative 
chemoradiation before total mesorectal excision. The 
radiation dose was 45-50.4Gy with fluoropyrimidine-based 
chemotherapy regimens. The influence of tumor 
characteristics and treatment regimen in tumor downstaging 
and regression grade (TRG) was tested using Mandard scoring 
system on surgical specimens. 
 
Results: Median age (range 33-85) was 67 years. The 
predominat cancer stages were stage II (38%) and stage IIIB 
(56%). Tumor downstaging occurred in 167 patients (69%), 
including 48 (19.8%) with ypT0 (documented T0 at surgery) 
and 166 (68.3%) with a satisfactory tumor regression grade, 
defined as TRG1-3. Identified predictive factors for 
pathologic complete response (pCR) included a planning 
target volume receiving 50.4Gy (PTV 50.4) and tumor 
location: PTV 50.4 ≤600cc (p=0.049) and upper rectal tumor 
location (p=0.004) were associated with higher pCR by 
univariate analysis. Multivariate analysis revealed a positive 
association of the TRG1-3 rate with longer intervals from 
chemoradiation to surgery (p=0.008): 5.4% at ≤5 weeks, 43.4% 
at 6-8 weeks and 51.2% at ≥9 weeks. Actuarial 3 and 5 years 
survivals were 95% and 90% for the group as a whole. Among 
ypT0 cases, the overall survival and relapse-free survival 
were 97% and 94%, respectively with a median follow-up of 
49.4 months, significantly different compared with the 
remaining group 89% and 74% respectively. There were no 
treatment-associated fatalities. Thirty-two of the 243 
patients (13%) experienced Grade III or IV toxicities (proctitis 
(8.6%), epithelitis (3.7%) and neutropenia (0.8%) during 
preoperative treatment.  
 
 
 
 
 
Conclusion: PTV50.4Gy and tumor location were identified as 
predictive factors of pCR for LARC treated with preoperative 
chemoradiation. PTV50.4 ≤600cc and upper rectal tumors are 
more likely to develop complete responses.  
Delay in surgery was identified as a favourable predictive 
factor for TRG1-3, Innovative strategies incorporating further 
time extension of the surgical interval can be safely 
explored. 
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Purpose or Objective: Neo-adjuvant chemoradiotherapy 
(CRT) is considered a standard approach for locally advanced 
rectal cancer. In this study we assessed the outcomes of 
patients who declined surgery following standard CRT in 
comparison to those who received surgery. 
 
Material and Methods: We evaluated all patients who 
received CRT for rectal cancer between February 2012 and 
December 2014 at our centre. All patients received 50.4Gy in 
1.8Gy fractions with concurrent capecitabine chemotherapy 
(825mg/m2 BD) daily throughout treatment. 61 patients 
received surgery (total mesorectal excision), performed 8-12 
weeks after completion of CRT (Group A). 12 patients 
received CRT alone and declined definitive surgery (Group B). 
These patients were monitored on a watch and wait 
approach. The primary end point of this study was disease 
free survival (DFS), with local recurrence being a secondary 
end point. 
 
Results: Group A comprised of 19/61 (31%) females and 
42/61 (69%) male, median age of this group was 66 years. 
59/61 (96.7%) patients showed an imaging response (defined 
as any improvement in disease) following CRT. Group B 
comprised of 6/12 (50%) male and female, median age of this 
group was 75 years. 9/12 (75%) patients showed an imaging 
response following CRT. Group A showed a local recurrence 
rate of 5/61 (8%) and a distant recurrance rate of 9/61 (15%) 
. Group B showed a recurrence rate of 4/12 (33%), all of 
which were local recurrences. There was no significant 
difference in overall recurrance rates between the two 
groups (t =0.90; p = 0.37). The disease free survival, using 
the Kaplin-Meier methodology, for Group A was 88% at one 
year and 80% at two years. For Group B it was 91% at one 
year and 66% at two years; the difference between the two 
groups being non-significant (log rank chi-square 1.35; 
p=0.245) 
 
Conclusion: This study suggests that a watch and wait 
approach after CRT is associated with increased risk of local 
relapse and a shorter disease free survival interval. The 
difference was not significant which might be due to small 
numbers in the watch and wait group. We continue to 
advocate surgery as the standard approach post CRT and 
await the results of prospective studies evaluating a watch 
and wait approach, as well as the use of imaging biomarkers 
to enable better prediction of outcome. 
 
 
